% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @ARTICLE{Gandaglia:298421, author = {G. Gandaglia and F. Barletta and S. Scuderi and P. Scilipoti and P. Rajwa and N. A. Huebner and J. Gomez Rivas and L. Ibanez and T. F. W. Soeterik and L. Bianchi and A. Mattei and C. Kesch$^*$ and C. Darr$^*$ and H. Guo and J. Zhuang and F. Zattoni and W. P. Fendler and G. Marra and A. Stabile and D. Robesti and D. Amparore and S. Joniau and R. Schiavina and J. M. Sierra and F. Porpiglia and M. Picchio and A. Chiti and A. Mottrie and R. C. N. van den Bergh and S. F. Shariat and F. Montorsi and A. Briganti}, title = {{E}xternal {V}alidation of {N}omograms for the {I}dentification of {P}elvic {N}odal {D}issection {C}andidates {A}mong {P}rostate {C}ancer {P}atients with {N}egative {P}reoperative {P}rostate-specific {M}embrane {A}ntigen {P}ositron {E}mission {T}omography.}, journal = {European urology oncology}, volume = {nn}, issn = {2588-9311}, address = {Amsterdam}, publisher = {Elsevier}, reportid = {DKFZ-2025-00277}, pages = {nn}, year = {2025}, note = {epub}, abstract = {Extended pelvic lymph node dissection (ePLND) is recommended in selected radical prostatectomy (RP) prostate cancer (PCa) patients for staging purposes. We aim to externally validate available tools to predict lymph node invasion (LNI) in men with negative preoperative prostate-specific membrane antigen positron emission tomography (miN0).Overall, 282 intermediate- to high-risk PCa patients with miN0 disease undergoing RP and ePLND at ten centers between 2016 and 2023 were identified. The Memorial Sloan Kettering Cancer Center (MSKCC); Amsterdam-Brisbane-Sydney; and Briganti 2017, 2019, and 2023 tools predicting LNI were validated externally using calibration plots, C-indexes, and decision-curve analyses to assess calibration, discrimination, and net benefit.Overall, 36 $(13\%)$ patients had LNI. The C-indexes of the MSKCC, Briganti 2017, Briganti 2019, Amsterdam-Brisbane-Sydney, and Briganti 2023 nomograms were $64\%,$ $69\%,$ $72\%,$ $64\%,$ and $77\%,$ respectively. The Briganti 2023 nomogram exhibited higher net benefit than the other available nomograms, and the use of a $5\%$ cutoff would have spared $47\%$ ePLND procedures (vs $14\%$ and $4.3\%$ for the Briganti 2019 and Amsterdam-Brisbane-Sydney nomograms, respectively) at the cost of missing only five $(3.8\%)$ LNI cases. Heterogeneity in patient selection and imaging protocols represents the main limitations.The Briganti 2023 nomogram outperformed other available tools in predicting LNI in men with miN0 PCa. The use of this tool resulted in a considerable number of unnecessary ePLND procedures spared and optimization of ePLND recommendations in a contemporary clinical setting.}, keywords = {Lymph node invasion (Other) / Magnetic resonance imaging–targeted biopsy (Other) / Nomogram (Other) / Pelvic lymph node dissection (Other) / Prostate cancer (Other) / Prostate-specific membrane antigen positron emission tomography (Other) / Radical prostatectomy (Other)}, cin = {ED01}, ddc = {610}, cid = {I:(DE-He78)ED01-20160331}, pnm = {899 - ohne Topic (POF4-899)}, pid = {G:(DE-HGF)POF4-899}, typ = {PUB:(DE-HGF)16}, pubmed = {pmid:39890547}, doi = {10.1016/j.euo.2025.01.004}, url = {https://inrepo02.dkfz.de/record/298421}, }